← All trials
NCT04874948
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 21, 2021
- Primary completion
- Oct 15, 2021
- Completion date
- Oct 15, 2021
- First posted
- May 6, 2021
- Last posted
- Oct 27, 2021
- Enrollment
- 6
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Ludwig Maximilians UniversityLead sponsor
- Ludwig Maximilians UniversitySponsor investigator
- Pharmaceutical Research Associates, Inc. (PRA)Overall official - principal investigator
- Hans Knöll Institute (HKI)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.